Jennison Associates
RARX

Jennison Associates’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Jennison Associates’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-202,500
Closed -$4.31M – 674
2017
Q1 		$4.31M Hold
202,500
– – ﹤0.01% 514
2016
Q4 		$3.08M Buy
+202,500
New +$2.75M ﹤0.01% 535

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates's RARX Position: Q2 2017 in Review

Jennison Associates sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2017, closing a stake of 202,500 shares — an estimated $4.31M sold.

Jennison Associates first reported a position in RARX in Q4 2016 and held it in 2 quarters. The position peaked at $4.31M in Q1 2017. 65 funds tracked by Wall St. Rank hold RARX as of Q2 2017.

  • Jennison Associates reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Jennison Associates sold 202,500 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2017, an estimated $4.31M.
  • Jennison Associates first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Jennison Associates's Ra Pharmaceuticals, Inc. Common Stock position peaked at $4.31M in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2017.

Based on Jennison Associates's 13F filing for Q2 2017, filed 4 Aug 2017.